A new study has evaluated the effectiveness of different treatment options for basal cell carcinoma. Learn more.

In a randomized trial, recurrence was higher after superficial curettage (SC) plus imiquimod cream than surgical excision (SE) in patients with nodular basal cell carcinoma (nBCC). At 5 years ...

Imiquimod is an ... TLR7/8 and used to treat basal cell carcinomas. The researchers employed various preclinical mouse tumor models of melanoma and breast cancer. What both tumors have in common ...

Imiquimod is an ... TLR7/8 and used to treat basal cell carcinomas. The researchers employed various preclinical mouse tumor models of melanoma and breast cancer. What both tumors have in common ...

Imiquimod is an ... TLR7/8 and used to treat basal cell carcinomas. The researchers employed various preclinical mouse tumor models of melanoma and breast cancer. What both tumors have in common ...

The goal of QR-02 is to treat and reduce dysplasia levels, potentially offering a curative solution for oral leukoplakia, an outcome that would mark a significant breakthrough in oral medicine. By ...

“What I say to a lot of our trainees is that not every actinic keratosis becomes a basal cell carcinoma or squamous ... off-label topical therapy with imiquimod if we’re just going to leave ...

QR-02’s active ingredient, imiquimod, is already FDA-approved for treating Actinic Keratosis, External Genital Warts, and Superficial Basal Cell Carcinoma (sBCC)—all superficial skin conditions.

WEDNESDAY, Jan. 29, 2025 (HealthDay News) -- For patients with nodular basal cell carcinoma (nBCC), it cannot be concluded that superficial curettage (SC) plus imiquimod cream, 5 percent, is ...

McDermott first revealed in 2021 that he had squamous cell carcinoma "several times." He added that he also has had basal cell cancer. According to the American Cancer Society, basal cell and ...